Novel insights in the diagnosis and treatment of non-small cell lung cancer: Post-translational modification of proteins
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-02 · 1881 (1) · 189507
DOI: 10.1016/j.bbcan.2025.189507 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-02. Verfasst von Yuting Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, PR China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Protein Processing, Post-Translational, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 258 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) is associated with a high incidence and mortality rate, imposing a significant economic burden worldwide. The development of standardized diagnostic and targeted therapeutic approaches is essential. Protein post-translational modifications (PTMs) play a critical role in regulating biological functions during both physiological and pathological states, as they reversibly and dynamically adjust protein activity in response to changes in internal and external conditions. Various types of PTMs, including ubiquitination, phosphorylation, glycosylation, Small Ubiquitin-like Modifier (SUMO)ylation, acetylation, palmitoylation, and lactylation, have been shown to correlate significantly with the onset, progression, metastasis, treatment, and drug resistance of NSCLC. These modifications are involved in the initiation and progression of NSCLC and are linked to patient survival outcomes. Additionally, different therapeutic modalities, such as chemotherapy, radiation therapy, and immunotherapy, can influence treatment efficacy by altering PTMs. However, the challenge of drug resistance significantly undermines therapeutic effectiveness and patient outcomes. This review emphasizes the importance of PTMs in drug resistance and highlights their potential to inform more precise treatment strategies for NSCLC, ultimately contributing to a reduction in disability-adjusted life years, which is of considerable practical importance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, PR China.
- Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, PR China. Electronic address: qfm2020jieli@yeah.net.
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China
Zitieren
APA
Sun, Y., Kong, W., Zhu, X., Chu, X., Wang, X., Zhu, G., He, X., & Li, J. (2026). Novel insights in the diagnosis and treatment of non-small cell lung cancer: Post-translational modification of proteins. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(1), 189507. https://doi.org/10.1016/j.bbcan.2025.189507
Vancouver
Sun Y, Kong W, Zhu X, Chu X, Wang X, Zhu G, et al. Novel insights in the diagnosis and treatment of non-small cell lung cancer: Post-translational modification of proteins. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(1):189507. doi:10.1016/j.bbcan.2025.189507
BibTeX
@article{Sun2026,
author = {Sun, Yuting and Kong, Weijia and Zhu, Xiaoyu and Chu, Xuelei and Wang, Xinmiao and Zhu, Guanghui and He, Xue and Li, Jie},
title = {Novel insights in the diagnosis and treatment of non-small cell lung cancer: Post-translational modification of proteins},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {1},
pages = {189507},
doi = {10.1016/j.bbcan.2025.189507}
}
EUVIMED